StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Protagonist Therapeutics's total assets was $885.54M at Jun 30, 2026. For fiscal 2025 it was $668.19M, down 10.3% from the year before. Over ten years it grew 46.3% a year on average. The highest annual figure on record is $744.73M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$668.19M-10.3%
FY2024Dec 31, 2024$744.73M+108.1%
FY2023Dec 31, 2023$357.95M+44.4%
FY2022Dec 31, 2022$247.93M-28.7%
FY2021Dec 31, 2021$347.70M+7.2%
FY2020Dec 31, 2020$324.47M+109.4%
FY2019Dec 31, 2019$154.92M+11.1%
FY2018Dec 31, 2018$139.47M-14.8%
FY2017Dec 31, 2017$163.73M+74.2%
FY2016Dec 31, 2016$93.99M+533.1%
FY2015Dec 31, 2015$14.85M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$885.54M+23.3%
Q1 FY2026Mar 31, 2026$697.46M-6.0%
Q4 FY2025Dec 31, 2025$668.19M-10.3%
Q3 FY2025Sep 30, 2025$701.69M+16.2%
Q2 FY2025Jun 30, 2025$718.01M+16.8%
Q1 FY2025Mar 31, 2025$742.13M+17.9%
Q4 FY2024Dec 31, 2024$744.73M+108.1%
Q3 FY2024Sep 30, 2024$603.86M+83.0%
Q2 FY2024Jun 30, 2024$614.63M+91.8%
Q1 FY2024Mar 31, 2024$629.28M+162.4%
Q4 FY2023Dec 31, 2023$357.95M+44.4%
Q3 FY2023Sep 30, 2023$330.02M+17.0%
Q2 FY2023Jun 30, 2023$320.47M+3.2%
Q1 FY2023Mar 31, 2023$239.86M-31.1%
Q4 FY2022Dec 31, 2022$247.93M-28.7%
Q3 FY2022Sep 30, 2022$282.17M-24.4%
Q2 FY2022Jun 30, 2022$310.51M-23.2%
Q1 FY2022Mar 31, 2022$348.30M+16.8%
Q4 FY2021Dec 31, 2021$347.70M+7.2%
Q3 FY2021Sep 30, 2021$373.18M+71.7%
Q2 FY2021Jun 30, 2021$404.23M+79.7%
Q1 FY2021Mar 31, 2021$298.07M+121.0%
Q4 FY2020Dec 31, 2020$324.47M+109.4%
Q3 FY2020Sep 30, 2020$217.32M+40.5%
Q2 FY2020Jun 30, 2020$224.98M+51.9%
Q1 FY2020Mar 31, 2020$134.90M+2.0%
Q4 FY2019Dec 31, 2019$154.92M+11.1%
Q3 FY2019Sep 30, 2019$154.63M+3.9%
Q2 FY2019Jun 30, 2019$148.11M+7.7%
Q1 FY2019Mar 31, 2019$132.25M-11.4%
Q4 FY2018Dec 31, 2018$139.47M-14.8%
Q3 FY2018Sep 30, 2018$148.86M+34.8%
Q2 FY2018Jun 30, 2018$137.47M+95.1%
Q1 FY2018Mar 31, 2018$149.24M+80.5%
Q4 FY2017Dec 31, 2017$163.73M+74.2%
Q3 FY2017Sep 30, 2017$110.42M+7.4%
Q2 FY2017Jun 30, 2017$70.48M–
Q1 FY2017Mar 31, 2017$82.67M–
Q4 FY2016Dec 31, 2016$93.99M–
Q3 FY2016Sep 30, 2016$102.84M–

More Protagonist Therapeutics figures

See a number that looks wrong?